Trial Profile
An Open Label, Two-part, Phase I/Randomized Phase II Study in Subjects With Relapsed/Refractory Multiple Myeloma to Determine a Dose of Afuresertib for Administration in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of Afuresertib With Carfilzomib Compared With Carfilzomib Alone (Part 2)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Afuresertib (Primary) ; Carfilzomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 03 May 2016 Status changed from recruiting to discontinued.
- 10 Mar 2015 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov
- 10 Mar 2015 Planned primary completion date changed from 1 Jun 2017 to 1 Apr 2016 as reported by ClinicalTrials.gov